Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
Carmine De Angelis(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Marta Bonotto(University of Udine), Francesco Schettini(Target (United States)), Fabio Puglisi(University of Udine), M. Cinausero(University of Udine), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Lorenzo Gerratana(National Cancer Institute), Mario Giuliano(Regione Campania), Donatella Iacono(University of Udine), Giuseppe Ciancia(University of Naples Federico II), Ferdinando Riccardi(Fatebenefratelli Hospital), Sabino De Placido, Massimo Di Maïo(University of Siena)
Cited by 3
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724